Taladegib for idiopathic pulmonary fibrosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 May 2024: Trial registered, NCT06422884
  2. 15 Nov 2024: Trial started, NCT06422884

The trials

NCT06422884: A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

State
Completed
Phase
Phase 2
People
213 taking part
Started
15 Nov 2024
Primary completion
21 Aug 2026
Arms
ENV-101 Low Dose (IPF Population), ENV-101 Mid Dose (IPF Population), ENV-101 High Dose (IPF Population)
Results
None posted
  1. 21 May 2024: Trial registered
  2. 15 Nov 2024: Trial started
  3. 21 Aug 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as ENV-101.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.